Author | Megan Garlapow, PhD


Consolidation to VRD Improves PFS in Patients With Newly Diagnosed Myeloma

December 05, 2016


Consolidation therapy with bortezomib/lenalidomide/dexamethasone (VRD) followed by maintenance with lenalidomide until progression or toxicity showed promising results over maintenance alone for patients with transplant-eligible multiple myeloma (NDMM) up to 65 years old, according to a final analysis of the EMN02 trial.

Cetuximab Improves Long-Term Disease Control in HPV-Negative HNSCC

April 07, 2016


Adding cetuximab (Erbitux) to induction chemotherapy and hyperfractionated or accelerated chemoradiation therapy produced long-term control for patients with HPV-, locoregionally advanced head and neck squamous cell carcinoma with a poor prognosis.

Motolimod Plus Cetuximab Proves Efficacious in Head and Neck Cancer

February 24, 2016


A neoadjuvant combination of motolimod plus cetuximab was found to increase the immune responses in both the blood and tumor microenvironment for patients with head and neck squamous cell carcinoma.